“This first time generic approval is another example of Par’s strategic investment in business development and execution on first-to-market and first-to-file products.”Ĭlick here to read the full press release. In his new role, Rockwell will oversee PAI’s growth strategy, further solidifying the company’s position as the number one manufacturer of quality liquid pharmaceuticals in the US.
(PAI) today announced the appointment of Brandon Rockwell as Chief Operating Officer, bringing 15 years of business development experience to the company. “Novitium has a history of impressive development and execution skills and we are pleased to have several products under development with them,” said Brandon Rockwell, Senior Vice President of Business Development. GREENVILLE, SC Pharmaceutical Associates, Inc. “We are proud to continue our tradition at Par of providing high quality, affordable medicines to patients.” Additionally, the product can be stored at room temperature which is an added convenience to patients,” said Domenic Ciarico, Executive Vice President and Chief Commercial Officer, Sterile and Generics. “We are pleased to offer this rare patient population suffering from HT-1 the first and only bioequivalent and therapeutically equivalent option to Orfadin ® capsules. Perform and train analysts on several analytical assays including wet chemistry, SDS-PAGE. Nitisinone capsules are indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Copper Prices Could See "Astronomical Rise" as Supply Concerns IncreaseĮndo International (NASDAQ ENDP) has announced that Novitium Pharma, a partner of Endo’s subsidiary Endo Ventures, received approval from the US Food and Drug Administration for a generic equivalent of Swedish Orphan Biovitrum’s Orfadin.10 Largest Producers of Gold by Country.
0 kommentar(er)
